Form 8-K Rubius Therapeutics, For: Sep 13

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 11/4/2026

1. AMD
2. BKNG
3. AMGN
4. DOX
5. DUOL
6. ANET
7. SWKS
8. CVS
9. SPY
10. XYZ

Go back to Form 8-K Rubius Therapeutics, For: Sep 13

Morgan Stanley on Rubius (RUBY) New Strategy and Restructuring: 'removes potential for near-term clinical catalyst'

September 13, 2022 9:48 AM EDT

Morgan Stanley analyst Jeffrey Hung reiterated an Equalweight rating and $1.50 price target on Rubius (NASDAQ: RUBY).

The analyst comments "Our Take: Update removes potential for near-term clinical catalysts. We acknowledge the potential advantages of the next-gen platform and understand streamlining the... More